A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Vistusertib (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.
- 27 Mar 2017 Planned initiation date changed from 15 Mar 2017 to 15 Apr 2017.
- 09 Mar 2017 New trial record